Kazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial
I'm PortAI, I can summarize articles.
Kazia Therapeutics announced that its drug paxalisib showed promising results in advanced breast cancer trials, including a 76% tumor reduction in a TNBC patient and immune reinvigoration. The findings were presented at the 2025 San Antonio Breast Cancer Symposium. Preliminary data also showed similar effects in HER2-positive patients. The results suggest paxalisib may target metastatic mechanisms not addressed by current therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments